NIVEGU.KNOW BEFORE YOU FLY

THE WORLD OF AVIATION.
YOUR JOURNEY, EXPLAINED.

NASDAQ / LIVE COMPANY INTELLIGENCE

BioCardia, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERBCDA
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / BCDA COVERAGE

What’s moving BioCardia, Inc. now

Current reporting with the operating signal separated from the noise.

01
BioCardia, Inc. informiert über den Stand der PMDA-Shonin-Einreichung zu CardiAMP HF und der FDA-Helix-Voranfrage

BioCardia, Inc. informiert über den Stand der PMDA-Shonin-Einreichung zu CardiAMP HF und der FDA-Helix-Voranfrage

The story matters when it changes BioCardia, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
BioCardia, Inc. Provides Update On PMDA CardiAMP HF Shonin Submission And FDA Helix Pre-Submission

BioCardia, Inc. Provides Update On PMDA CardiAMP HF Shonin Submission And FDA Helix Pre-Submission

The story matters when it changes BioCardia, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
BioCardia, Inc. Secures Japanese Patent for Innovative Catheter Delivery System in Cell Therapy

BioCardia, Inc. Secures Japanese Patent for Innovative Catheter Delivery System in Cell Therapy

The story matters when it changes BioCardia, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: official volume, pricing, inventory and segment margin.
04
BioCardia, Inc. (BCDA) Q1 2024 Earnings Call Transcript

BioCardia, Inc. (BCDA) Q1 2024 Earnings Call Transcript

Investors are testing whether BioCardia, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
05
BioCardia, Inc. (BCDA) Q3 2023 Earnings Call Transcript

BioCardia, Inc. (BCDA) Q3 2023 Earnings Call Transcript

Investors are testing whether BioCardia, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
06
BioCardia, Inc. (BCDA) Upgraded to Buy: Here's What You Should Know

BioCardia, Inc. (BCDA) Upgraded to Buy: Here's What You Should Know

The story matters when it changes BioCardia, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest BCDA filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-08-12 · Period 2026-06-30SEC ↗10-QQuarterly financial reportFiled 2026-05-15 · Period 2026-03-31SEC ↗10-KAnnual financial reportFiled 2026-03-24 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-09-23 · Period 2026-09-23SEC ↗8-KMaterial company eventFiled 2026-09-21 · Period 2026-09-21SEC ↗8-KMaterial company eventFiled 2026-09-10 · Period 2026-09-10SEC ↗DEF 14AProxy and shareholder meetingFiled 2025-11-03 · Period 2025-12-02SEC ↗4Official SEC filingFiled 2026-09-23 · Period 2026-09-23SEC ↗
EARNINGS / QUARTERLY TRACKER

BioCardia, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.